Patent · US Active

Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1

US8329897B2 · kind B2 · utility

19Cited by
47References
17Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJul 25, 2008
Grant dateDec 11, 2012
Priority date—
Expiry dateFeb 17, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are syntheses of 11β-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticoid effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.